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Introduction: Comparison of side-to-side brachiocephalic arterio-
venous fistula (BCAVF) with ligation of the perforating vein with
end-to-side BCAVF.
Report: All side-to-side with ligation of the perforating vein and
end-to-side BCAVFs which were created in two hospitals were
followed up to determine complications and patency rate of AVFs.
Forty-four patients (24 side-to-side) entered the study but two
patients censored from analysis due to early mortality. Patients of
both groups were free of steal syndrome and venous hypertension.
There were no significant differences in maturation time and compli-
cations between two groups. Respectively 2 and 3 failures occurred in
side-to-side and end-to-side groups (P> 0.05). One year patency rate
was 95% and 86% for side-to-side and end-to-side groups respectively.
Discussion: Although there was no significant difference regarding
primary and secondary access failure during follow up period,
one year patency rate was higher in side-to-side group using life
table analysis. Also, there was no significant difference regarding
complications. This may show end-to-side BCAVF has no superiority
to our new technique.
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We report a case where an 8 mm mushroom patent ductus
arteriosus occluder was used in a 59-year-old woman to resolve
a renal artery-inferior vena cave fistula that occurred following
a right nephrectomy performed 27 years previously. Complete
occlusion of the fistula was achieved. This case highlights the novel
use of a PDA occluder and provides evidence that this may be
a viable technique for the management of arteriovenous fistulas
with similar vessel relationships, anatomical characteristics, and
occlusion demands as the fistula described in this report.
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Cyclo-oxygenase-2 inhibitors are thought to be associated with an
increased risk of cardiovascular events as a result of alteration
in hemostasis. We report the case of a 39-year-old patient with
minimal risk factors for cardiovascular disease who was
prescribed a cyclo-oxygenase-2 inhibitor. He presented with
symptoms of distal vessel thrombosis which was confirmed with
angiography; this provides further evidence of the possible
association of cyclo-oxygenase-2 inhibitors and thrombus
formation.doi:10.1016/j.ejvs.2008.11.020
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